I like:
- Increase of 121% on the March quarter 2019.
- Financial year-end Cash Receipts to June 2019 of $32,221,000 wereup 36% compared to the prior financial year (to June 2018).- This indicates that more EPP patients in Europe arereceiving treatment with SCENESSE® and we look forward to the time the same treatment access can be provided toAmerican EPP patients who have no current alternatives.”
- Net Cash from Operations was positive by $8,618,000 in the June quarter 2019. Net Cash from Operations for thetwelve months to 30 June 2019 was a positive $18,382,000 compared to a positive $11,693,000 in the same twelvemonth period to 30 June 2018.
- Increasing cash balance - Cash Balance as at 30 June2019 increased to $54,269,000, compared to $44,975,000 as at 31 March 2019 and $36,198,000 as at 30 June 2018.
Very positive outlook and building blocks foundation.
Well done!
- Forums
- ASX - By Stock
- CUV
- Ann: Appendix 4C - quarterly
CUV
clinuvel pharmaceuticals limited
Add to My Watchlist
4.53%
!
$11.76

Ann: Appendix 4C - quarterly, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$11.76 |
Change
0.510(4.53%) |
Mkt cap ! $589.4M |
Open | High | Low | Value | Volume |
$11.25 | $11.81 | $11.14 | $1.328M | 114.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | $11.75 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.81 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 11.650 |
1 | 100 | 11.600 |
1 | 687 | 11.580 |
1 | 800 | 11.520 |
2 | 273 | 11.500 |
Price($) | Vol. | No. |
---|---|---|
11.810 | 2000 | 1 |
11.870 | 1000 | 1 |
11.980 | 604 | 2 |
11.990 | 150 | 1 |
12.000 | 5000 | 1 |
Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |